Artificial Coma/Medically Induced Coma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The artificial coma/medically induced coma market is expected to register a CAGR of 3% over the forecast period.

COVID-19 significantly impacted the market since many surgeries were canceled or delayed due to the global lockdown implemented to reduce the spread of COVID-19. For instance, a study published in March 2022 in Springer revealed that the lowest number of monthly caseloads of neurosurgical procedures was recorded during the first wave of the pandemic. The first quarter of 2021 recorded the lowest number of quarterly surgical procedures over the entire 3-year period. As the number of neurosurgical procedures reduced, the demand for artificial coma lowered, which significantly impacted the market. However, as the pandemic restrictions are eased, the market is expected to grow considerably due to the rise in complications associated with the brain and the increase in emergency and lengthy surgical procedures across the globe.

Factors such as an increase in cases of brain injury, brain diseases, rise in surgical procedures coupled with the increased adoption of artificial coma to protect the brain during major neurosurgery are expected to bolster the market growth over the study period. For instance, according to the American Cancer Society 2023 update, about 24,810 malignant tumors of the brain or spinal cord (14,280 in males and 10,530 in females) are expected to be diagnosed in 2023 in the United States. These numbers would be much higher if benign (non-cancer) tumors were also included. Moreover, a rise in the adoption of artificial coma drugs in major brain surgeries is further likely to contribute to market growth. For instance, according to the article published in January 2022 in PubMed, as a person loses consciousness, propofol causes a specific reorganization of the brain's neural networks. The brain network's response to propofol in individuals with consciousness problems may disclose the patient's underlying potential for consciousness.

Furthermore, the presence of key players and their strategic product launches are expected to bolster market growth. For instance, in August 2022, Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, offered Propofol as the first product within its KinetiX platform of RTA syringe products at the Annual National Pharmacy Purchasing Association Conference. The KinetiX RTA platform, intended to streamline workflow and enhance efficient care delivery, offers its first product, a new Propofol Syringe.

Thus, the high prevalence of brain-related diseases and the rise in the adoption of artificial coma is expected to bolster the market growth. However, the side effect such as confusion, delirium, immobility etc., associated with the artificial coma is likely to hinder the market growth over the forecast period.

Artificial Coma/Medically Induced Coma Market Trends

Traumatic Brain Injury Segment is Expected to Witness a Positive Growth Over the Forecast Period

Traumatic Brain Injuries (TBI) include car and motorcycle accidents, sports injuries, abusive head trauma, gunshot wounds, and workplace injuries. The TBI segment is expected to witness significant growth in the studied market owing to the increase in the burden of TBI across the globe and the rise in medically induced coma for TBI-related surgical procedures. For instance, as per the data from the Brain Injury Association of America (BIAA) published in March 2021, every nine seconds, there is one person in the United States who sustains a brain injury. This accounts for more than 3.5 million injuries every year. Hence, with such a high number of people facing TBI, the segment studied is believed to witness growth due to the rise in demand for proper artificial coma for the patient to conduct major surgeries on the brain.

Furthermore, an increase in government initiatives to support TBI patients is expected to bolster the segment growth over the study period. For instance, in March 2023, the FY23 Defense Appropriations Act provided funding for Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) to support research into the treatment, prevention, and detection of traumatic brain injury (TBI) and improved psychological health. Similarly, countries like India are facing the challenge of TBI caused by road accidents as the number of road accidents occurring in these countries is increasing every year. For instance, as per the data by National Crime Records Bureau published in August 2022, the number of road accidents in India increased from 3,68,828 in 2020 to 4,22,659 in 2021. Furthermore, other data from the Indian Head Injury Foundation published in its 2021 report stated that over one million people across the country suffer from severe head injuries every year, and around 60% of TBI in India were caused by road accidents. Hence, observing the given statistics, it is believed that increasing road accidents that are causing TBIs are expected to contribute significantly to the growth of the studied segment.

Thus, owing to the increase in the TBI, the rise in road accidents, and the increase in investment by the government to undergo TBI-related research and development, the studied segment is expected to witness significant growth over the forecast period.

North America is Expected to Witness a Significant Growth Over the Forecast Period

North America is expected to witness significant market growth owing to better healthcare infrastructure and the presence of major industry players. Moreover, an increase in the prevalence of brain injuries is further expected to bolster market growth. For instance, as per the May 2022 update by the Canadian Cancer Society, 3,200 Canadians were diagnosed with brain and spinal cord cancer in Canada. Furthermore, as per the May 2023 update by CDC, every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes. High occurrence of stroke leads to brain complications, which require complex surgeries, which thereby utilize the artificially induced coma and thus lead to market growth over the forecast period.

Furthermore, the presence of key players and their strategic product launches are expected to augment the market growth in the North America region. For instance, in April 2022, Avet Pharmaceuticals Inc. launched its Propofol Injectable Emulsion, USP 10 mg/mL, in 20, 50, and 100 ml Single Patient-Use Vials, an AB-rated generic equivalent of DIPRIVAN (propofol) Injectable Emulsion USP, following its abbreviated new drug application approval from the Food and Drug Administration (FDA).

Thus, due to the increase in brain-related diseases and the rise in strategical product launches, North America is expected to witness significant growth over the forecast period.

Artificial Coma/Medically Induced Coma Industry Overview

The artificial coma/medically induced coma market is moderately fragmented in nature due to the presence of several companies operating globally as well as regionally. A few of the major companies in the market are B Braun SE, Baxter Healthcare Corporation, Fresenius SE & Co. KGaA, Aspen Holdings, etc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.